NewsDialy
Houston biotechnology company Decoy Therapeutics, Inc. (NASDAQ: DCOY) announced on June 26, 2026, that it is raising up to $21 million through a private placement financing.
The capital raise centers on advancing the company's Designable Multi-Antivirals platform — a technology Decoy describes as an entirely new category of antiviral medicine.
What Designable Multi-Antivirals Are — and Why the Distinction Matters Decoy's core technology, trademarked as D-MAVs™, is engineered to target viral mechanisms that are conserved across entire virus families rather than attacking features unique to a single virus or strain.
That approach differs from most conventional antivirals, which are developed against one specific pathogen and often lose effectiveness when that pathogen mutates.
Keep reading